Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13759270 | 0.93 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C9TOP2AMAPT | |
| SCHEMBL1602906 | 0.87 | GRM4 (0.39) | MAPTHPGDAURKBGRM4RAB9A | |
| SCHEMBL13759272 | 0.81 | GRM4 (0.39) | MAPTHPGDGRM4 | |
| SCHEMBL430725 | 0.79 | AURKA (0.43) | CYP3A4CYP2D6CYP2C9SYKAURKA | |
| SCHEMBL13759184 | 0.77 | AURKA (0.44) | CYP3A4CYP2D6CYP2C9SYKAURKA | |
| SCHEMBL460359 | 0.76 | AURKA (0.42) | CYP3A4CYP2D6CYP2C9MAPTHPGD | |
| SCHEMBL427074 | 0.76 | AURKA (0.41) | MAPTSYKAURKACCNA2CDK2 | |
| SCHEMBL425180 | 0.76 | AURKA (0.42) | MAPTHPGDSYKAURKACCNA2 | |
| SCHEMBL12706393 | 0.76 | AURKA (0.43) | TOP2AHPGDSYKAURKAGRM4 | |
| SCHEMBL423890 | 0.75 | KDM4E (0.41) | CYP3A4CYP2D6CYP2C9MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | claimed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | claimed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | CYP3A4 2294/4885CYP2D6 1892/4885CYP2C9 1934/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | CYP3A4 4855/4885CYP2D6 4828/4885CYP2C9 4880/4885 |
| US-20060122156-A1 | Heteroaryl compounds | IL2, CCL11, IL4 | CYP3A4 187/4885CYP2D6 317/4885CYP2C9 449/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | CYP3A4 458/4885CYP2D6 879/4885CYP2C9 322/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | CYP3A4 4855/4885CYP2D6 4828/4885CYP2C9 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.